Vimta Labs Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 2/6
Vimta Labs verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 27%, während die Gewinne der Branche Life Sciences jährlich um gewachsen und zwar um 9.8%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 13.4%. Die Eigenkapitalrendite von Vimta Labs beträgt 12.8% und die Nettomargen betragen 12.9%.
Wichtige Informationen
27.3%
Wachstumsrate der Gewinne
27.3%
EPS-Wachstumsrate
| Life Sciences Wachstum der Industrie | 11.2% |
| Wachstumsrate der Einnahmen | 13.7% |
| Eigenkapitalrendite | 12.9% |
| Netto-Marge | 12.9% |
| Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
There's Reason For Concern Over Vimta Labs Limited's (NSE:VIMTALABS) Massive 31% Price Jump
Sep 06
It Looks Like Shareholders Would Probably Approve Vimta Labs Limited's (NSE:VIMTALABS) CEO Compensation Package
Jul 12Vimta Labs (NSE:VIMTALABS) Seems To Use Debt Quite Sensibly
Jun 12Market Might Still Lack Some Conviction On Vimta Labs Limited (NSE:VIMTALABS) Even After 26% Share Price Boost
Apr 26It's A Story Of Risk Vs Reward With Vimta Labs Limited (NSE:VIMTALABS)
Jan 06If EPS Growth Is Important To You, Vimta Labs (NSE:VIMTALABS) Presents An Opportunity
Jul 14Vimta Labs (NSE:VIMTALABS) Has Announced A Dividend Of ₹2.00
Jun 03Vimta Labs' (NSE:VIMTALABS) Dividend Will Be ₹2.00
May 06A Look At The Intrinsic Value Of Vimta Labs Limited (NSE:VIMTALABS)
Dec 07Here's Why We Think Vimta Labs (NSE:VIMTALABS) Might Deserve Your Attention Today
Nov 06Vimta Labs (NSE:VIMTALABS) Is Due To Pay A Dividend Of ₹2.00
Jun 02Does Vimta Labs (NSE:VIMTALABS) Deserve A Spot On Your Watchlist?
Dec 06Here's Why Vimta Labs (NSE:VIMTALABS) Can Manage Its Debt Responsibly
Oct 27We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Vimta Labs Limited's (NSE:VIMTALABS) CEO For Now
Jun 29Does Vimta Labs (NSE:VIMTALABS) Have A Healthy Balance Sheet?
Jun 19Here's Why Vimta Labs (NSE:VIMTALABS) Can Manage Its Debt Responsibly
Mar 09Vimta Labs Limited's (NSE:VIMTALABS) Stock Is Going Strong: Have Financials A Role To Play?
Jan 20Did You Miss Vimta Labs' (NSE:VIMTALABS) 87% Share Price Gain?
Dec 30Does Vimta Labs (NSE:VIMTALABS) Have A Healthy Balance Sheet?
Dec 09
Here's What We Learned About The CEO Pay At Vimta Labs Limited (NSE:VIMTALABS)
Nov 17Vimta Labs Limited's (NSE:VIMTALABS) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Oct 21Here's Why Vimta Labs (NSE:VIMTALABS) Has A Meaningful Debt Burden
Sep 10Vimta Labs Limited's (NSE:VIMTALABS) Price Is Out Of Tune With Earnings
Aug 05Vimta Labs Limited's (NSE:VIMTALABS) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Jul 14Aufschlüsselung der Einnahmen und Ausgaben
Wie Vimta Labs Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 24 | 3,176 | 411 | 1,056 | 0 |
| 31 Mar 24 | 3,193 | 410 | 1,058 | 0 |
| 31 Dec 23 | 3,212 | 413 | 1,044 | 0 |
| 30 Sep 23 | 3,169 | 415 | 1,019 | 0 |
| 30 Jun 23 | 3,234 | 483 | 999 | 0 |
| 31 Mar 23 | 3,190 | 482 | 980 | 0 |
| 31 Dec 22 | 3,109 | 473 | 975 | 0 |
| 30 Sep 22 | 3,009 | 488 | 937 | 0 |
| 30 Jun 22 | 2,965 | 453 | 879 | 0 |
| 31 Mar 22 | 2,787 | 413 | 834 | 0 |
| 31 Dec 21 | 2,644 | 372 | 771 | 0 |
| 30 Sep 21 | 2,557 | 336 | 738 | 0 |
| 30 Jun 21 | 2,396 | 314 | 718 | 0 |
| 31 Mar 21 | 2,110 | 214 | 665 | 0 |
| 31 Dec 20 | 1,945 | 137 | 637 | 0 |
| 30 Sep 20 | 1,873 | 104 | 635 | 0 |
| 30 Jun 20 | 1,694 | 37 | 594 | 0 |
| 31 Mar 20 | 1,811 | 68 | 653 | 0 |
| 31 Dec 19 | 1,914 | 136 | 684 | 0 |
| 30 Sep 19 | 1,906 | 140 | 673 | 0 |
| 30 Jun 19 | 2,025 | 200 | 671 | 0 |
| 31 Mar 19 | 2,130 | 253 | 665 | 0 |
| 31 Dec 18 | 2,126 | 236 | 666 | 0 |
| 30 Sep 18 | 2,071 | 245 | 646 | 0 |
| 30 Jun 18 | 1,970 | 218 | 621 | 0 |
| 31 Mar 18 | 1,836 | 164 | 595 | 0 |
| 31 Dec 17 | 1,693 | 134 | 562 | 0 |
| 30 Sep 17 | 1,602 | 104 | 548 | 0 |
| 30 Jun 17 | 1,552 | 83 | 534 | 0 |
| 31 Mar 17 | 1,538 | 106 | 503 | 0 |
| 31 Dec 16 | 1,468 | 94 | 460 | 0 |
| 30 Sep 16 | 1,376 | 74 | 433 | 0 |
| 30 Jun 16 | 1,344 | 79 | 349 | 0 |
| 31 Mar 16 | 1,247 | 64 | 382 | 0 |
| 31 Dec 15 | 1,202 | 63 | 486 | 0 |
| 30 Sep 15 | 1,157 | 59 | 475 | 0 |
| 30 Jun 15 | 1,068 | 45 | 316 | 0 |
| 31 Mar 15 | 1,073 | 51 | 343 | 0 |
| 31 Dec 14 | 1,082 | 52 | 477 | 0 |
| 30 Sep 14 | 1,140 | 85 | 466 | 0 |
| 30 Jun 14 | 1,195 | 114 | 455 | 0 |
| 31 Mar 14 | 1,183 | 132 | 443 | 0 |
| 31 Dec 13 | 1,175 | 130 | 395 | 0 |
| 30 Sep 13 | 1,130 | 104 | 388 | 0 |
Qualität der Erträge: VIMTALABS hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: VIMTALABSDie aktuellen Gewinnspannen (12.7%) sind niedriger als im letzten Jahr (15.1%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: VIMTALABSIn den letzten 5 Jahren sind die Einnahmen von 27% pro Jahr erheblich gestiegen.
Beschleunigtes Wachstum: VIMTALABSDas Unternehmen hat im vergangenen Jahr ein negatives Gewinnwachstum verzeichnet, so dass es nicht mit seinem 5-Jahres-Durchschnitt verglichen werden kann.
Erträge im Vergleich zur Industrie: VIMTALABS hatte im vergangenen Jahr ein negatives Gewinnwachstum (-14.9%), was einen Vergleich mit dem Branchendurchschnitt Life Sciences (2.6%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: VIMTALABSDie Eigenkapitalrendite des Unternehmens (12.8%) wird als niedrig angesehen.